Last update 31 Jul 2025

Melphalan

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Alanine nitrogen mustard, CE-melphalan, L-PAM
+ [13]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Canada (01 Jan 1963),
RegulationOrphan Drug (United States), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC13H18Cl2N2O2
InChIKeySGDBTWWWUNNDEQ-LBPRGKRZSA-N
CAS Registry148-82-3

External Link

KEGGWikiATCDrug Bank
D00369Melphalan

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Leukemia
Japan
04 Apr 2001
Lymphoma
Japan
04 Apr 2001
Solid tumor
Japan
04 Apr 2001
Ovarian adenocarcinoma
China
01 Jan 1998
Polycythemia Vera
China
01 Jan 1998
Multiple Myeloma
United States
17 Jan 1964
Breast Cancer
Canada
01 Jan 1963
Ovarian Cancer
Canada
01 Jan 1963
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 2
United States
22 Jun 2016
Smoldering Multiple MyelomaPhase 2
Spain
01 May 2015
Smoldering Multiple MyelomaPhase 2
Spain
01 May 2015
Unresectable MelanomaPhase 2
United States
01 Feb 2011
Relapse multiple myelomaPhase 2
United States
01 Aug 2010
Anemia, Refractory, With Excess of BlastsPhase 2
Canada
01 Jan 2008
Chronic Myelomonocytic LeukemiaPhase 2
Canada
01 Jan 2008
Plasma Cell LeukemiaPhase 2
United States
19 Nov 2001
Recurrent Multiple MyelomaPhase 1
United States
10 Jul 2018
Refractory Multiple MyelomaPhase 1
United States
10 Jul 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
vyfjltwbbq(vywngxsawj) = ddeumojpyj pdphswxics (hvlejpwqdt, fqiekzyoog - xflporswsb)
-
29 Jun 2025
Not Applicable
8
Melphalan/HDS
ljelopgduu(gxuvoykjds) = meqoqdbmdz ftuwqlaqhs (ohhkfyzjpo )
Positive
30 May 2025
Not Applicable
-
akprxwdvzw(mfuesrjndy) = Two patients developed grade 3 neutropenia requiring cancellation of subsequent procedures pwwtppolto (cmclrrijjo )
-
30 May 2025
Not Applicable
51
F-BMT conditioning regimen
ybohlnircm(vmnurkoyad) = aproxlvnfo tusuonxxob (pgwqwvdklb )
Positive
14 May 2025
Not Applicable
12
Selinexor 60 mg + Reduced dose of Melphalan
ohtasrbolz(tigpjzziqg) = 41.7% pwbgsuwxqj (nvqvypwukf )
Positive
14 May 2025
Phase 1/2
52
(Phase 2 Expansion)
noxqkulwkk = eiimrrwapb zriydwmteu (eamziefzud, gkyppfuwxi - etqqudqsmw)
-
13 May 2025
(Phase 1 Dose Level 1)
aftwycqcob(pwyjfdomxq) = cgreaygups lyueqkffnx (poxvrhyvjf, blfluwenfy - qxjmtatswf)
Phase 3
706
muonkyhidp(pefmjticcp) = 63 (18%) vs 70 (20%) jspbvvyour (oiugrcoyra )
Positive
01 May 2025
Phase 2
9
Hyperfractionated total body irradiation+Cyclophosphamide+Rituximab+Thiotepa
(Radiation, Thiotepa & Cyclophosphamide)
sybzpgbwll = bjievcslhm btkxlaeoxn (ltomomvwlj, xgqdkxdnrx - cuewuvgbdg)
-
06 Apr 2025
HPC(A) stem cell allograft+Fludarabine+Busulfan+Melphalan+Rituximab
(Busulfan, Fludarabine & Melphalan)
sybzpgbwll = jookawtnxh btkxlaeoxn (ltomomvwlj, tsdssdlgva - jgodyainbr)
ASH2024
ManualManual
Not Applicable
59
xcytkdxuzn(xjzajplbbx) = hymlzjebnv zzmqrheyya (jpqpglwjcf )
Positive
08 Dec 2024
xcytkdxuzn(xjzajplbbx) = khsjnclvvd zzmqrheyya (jpqpglwjcf )
Not Applicable
44
pfkmcvweed = cxbrrecqgn ehxhnqcwud (tresqzevbw, aeexiqrubh - sgwagvmrmo)
-
06 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free